The global breast cancer liquid biopsy market is to increase from US$ 268.3 million in 2020 to US$ 677.3 million by 2025 with a compound annual growth rate (CAGR) of 20.3% for the period 2020-2025. The development of new cancer drugs by making viable treatment choices due to increased research and development (R&D) activities catalyse the market growth for breast cancer liquid biopsy. It is used to recognize or catch the intact genomics history of breast cancers, or to diagnose cancerous biomarkers at an early stage to better provide successful prevention and healthcare services. According to the World Health Organisation (WHO), breast cancer is one of the most prevalent forms of cancer in women, with about 2.1 million women suffering from breast cancer each year. Also, in 2018, nearly 627,000 people died of breast cancer. As a result, the increased case of breast cancer is expected to accelerate the need for breast cancer liquid biopsy. The research report on the global breast cancer liquid biopsy industry provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the breast cancer liquid biopsy industry. The data in this report is targeted for business and industry practitioners and specifically intended to assist in the explanation, direction, and to understand of the potential of the breast cancer liquid biopsy markets. The study focuses on providing readers with an understanding of developments in the industry, market segments, market forecasts, leading players, and market drivers and inhibitors.
- Goals and objectives of the study
- Define key market trends, innovations, opportunities, and factors influencing the global breast cancer liquid biopsy market and its sub-segments.
- Identify and analyze primary industry categories and their respective frameworks for the breast cancer liquid biopsy global market.
- Predict the total size of the breast cancer liquid biopsy market internationally and analyze it based on the circulating biomarkers, end-users and region.
- Classify primary players and assess the business environment based on recent developments and segment revenue.
Chapter 2, "Market Overview" provides an overview of the breast cancer liquid biopsy market. The chapter includes macro-economic factors, market determinants (includes market drivers, restraints, opportunities, and challenges), value chain analysis, technology/product roadmap, Porter 5 force model analysis, market growth opportunity analysis.
Chapter 3 "Segment Analysis" of the study deals with the different sub-segments of the market to calculate reliable market forecasts. The breast cancer liquid biopsy market was segmented based on circulating biomarkers and end-users. The chapter provides an in-depth analysis of the market segments of the breast cancer liquid biopsy market, year-on-year growth projections that enable readers to identify potential market growth areas.
- Market Segmentation
- Based on circulating biomarkers, the global demand for breast cancer liquid biopsy is segmenting into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs).
- Based on end-users, the market is segmenting into reference laboratories, hospitals and physicians laboratories and others.
Chapter 4, "Regional Analysis" includes an in-depth analysis of the breast cancer liquid biopsy market by regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The report also includes a comprehensive analysis of the market in key countries such as the United States, Canada, Germany, France, Italy, Spain, China, India, Japan, the GCC, South Africa, Brazil, Mexico, and the rest of the world. Regional insight helps market competitors to make crucial decisions about their company. Individualized, country-wise, and segment-wise analyses by region allow readers of the breast cancer liquid biopsy market report to explore the potential of the market in different geographies. For each year's growth projections and a global share of value, this section is a vital part of the report.
Chapter 5 "Competitive Analysis" of the report includes company shares analysis, a list of acquisitions, mergers, collaboration, and the introduction of new products.
Chapter 6 "Company Profile" of the report also covers key industry players working on the breast cancer liquid biopsy market. Some of the prominent competitors in the breast cancer liquid biopsy market are QIAGEN N.v., Roche Diagnostics, Illuma,Inc., Myriad Genetics, Menarini Silicon Biosystems, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc. and Biodesix, Inc. The report also discusses the business strategies adopted by the players at the global, regional, and country-level. The study also focuses on various businesses or inorganic business development strategies for expanding consumer networks through product formation, organization extension, partnerships, mergers, and acquisitions.
The study offers an exhaustive summary and estimate of the global breast cancer liquid biopsy market. It includes in-depth qualitative and quantitative analyses in the report that aligned with the goals and objectives of our customers. Projections have been confirmed by comprehensive primary and secondary analysis. The study will encourage clients to invest in the breast cancer liquid biopsy market based on the current business situation, trends, and potential developments in the segments. Understanding the requirement of the client, the report delivers specialist insights into the global breast cancer liquid biopsy market, its products, and market patterns.
